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Abstract This study aimed at obtaining an in-depth mapping
of expressional changes of the cerebral microvasculature after
transient global cerebral ischemia (GCI) and the impact on
these GCI-induced expressional changes of post-GCI treat-
ment with a mitogen-activated protein kinase kinase
(MEK1/2) inhibitor. GCI was induced in male Wistar rats
followed by treatment with either vehicle or the MEK1/2 in-
hibitor U0126 every 12 h post-GCI. Seventy-two hours after
GCI or sham surgery, the cerebral microvasculature was iso-
lated and the protein content analysed with state-of-the-art
mass spectrometry. The proteomic profile of the isolated ce-
rebral microvasculature 72 h after GCI (compared to sham)
indicated that the main expressional changes could be divided
into nine categories: (1) cellular respiration, (2) remodelling of
the extracellular matrix, (3) decreased contractile phenotype,
(4) clathrin-mediated endocytosis, (5) ribosomal activity, (6)
expression of chromatin structure-related proteins, (7) altered
synaptic activity, (8) altered G-protein signalling and (9) in-
stability of the membrane potential. Treatment with U0126
partly normalized the expression of one or more of the pro-
teins in all nine categories. Flow cytometry confirmed key
findings from the proteome such as upregulation of the extra-
cellular proteins lamininβ2 and nidogen2 (p < 0.05) after
GCI. These results provide valuable molecular insight into
the broad and complex expressional changes in the cerebral
microvasculature after GCI and the effect of early MEK1/2
inhibitor treatment on these changes.
Keywords Cerebral microvasculature . Extracellular matrix
remodelling . Global cerebral ischemia .MEK1/2 inhibitor
treatment . Proteomics
Introduction
The cerebral vasculature is highly specialized to ensure a sta-
ble environment in the central nervous system with a contin-
uous and constantly adapting cerebral blood flow (CBF). Half
of the cerebral vascular resistance determining CBF resides in
the extra-parenchymal arteries on the brain surface, which
regulate input blood supply to the cerebral parenchyma. The
other half of the cerebral resistance resides in the
intraparenchymal microvasculature, which regulates the local
CBF to meet the changing metabolic demands of active brain
regions by a complex interplay of neurons, astrocytes and the
intraparenchymal vasculature (Edvinsson and Krause 2002;
Attwell et al. 2010).
Global cerebral ischemia (GCI) was previously shown to
cause pathophysiological changes in the extra-parenchymal
vasculature 48 and 72 h after the insult. Increased expression
of contractile endothelin B (ETB) and 5-hydroxytryptamine
1B (5-HT1B) receptors and the calcium channel transient re-
ceptor potential canonical 1 and 6 in the vascular smooth
muscle cells (VSMCs) of the large extra-parenchymal arteries
correlated with a decrease in forebrain blood flow (Johansson
et al. 2012, 2014, 2015). The increased contractility of the
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extra-parenchymal arteries is thought to contribute to the de-
velopment of delayed neurological damage found in the days
after GCI via decreased CBF (Edvinsson and Povlsen 2011;
Johansson et al. 2012, 2014, 2015). Delayed neurological
damage is a pathological event found in the brain 2–7 days
after the initial episode of transient GCI where neurons in
selective vulnerable areas succumb and die. The brain regions
affected depend on the severity and length of the episode of
transient GCI, and delayed neurological damage has been
found in the hippocampus, caudate putamen, thalamus, cere-
bellum and cerebral cortex (Neumann et al. 2013; Petito et al.
1987; Pulsinelli et al. 1982; Zeng and Xu 2000). Delayed
neurological damage causes delayed neurological deteriora-
tion and mortality in patients, and finding a treatment strategy
that could prevent this delayed deterioration would improve
the outcome and save many lives.
We have previously shown that treatment with a mitogen-
activated kinase kinase (MEK1/2) inhibitor after GCI
prevented upregulation of contractile receptors in the extra-
parenchymal arteries and more importantly decreased delayed
neurological damage, prevented the development of delayed
mortality and improved overall well-being of the rats treated
(Johansson et al. 2014). Furthermore, MEK1/2 activation has
been shown to be involved in the activation of metalloprotein-
ases and proinflammatory molecules causing blood-brain bar-
rier (BBB) breakdown and inflammation, thereby worsening
cerebral ischemic damage (Edvinsson and Povlsen 2011). Our
overall hypothesis is that inhibiting the broad MEK1/2 signal-
ling pathway transiently after cerebral ischemia and GCI pre-
vents multiple damaging cellular processes in the extra-
parenchymal vasculature, and this novel treatment approach
targeting multiple processes will improve overall outcome in
patients suffering from cerebral ischemia and GCI (Edvinsson
and Povlsen 2011). In addition to preventing pathological
changes in the extra-parenchymal vasculature, it seems likely
that this treatment strategy may also prevent delayed patholog-
ical changes in the intraparenchymal cerebral vasculature and
brain parenchyma (neurons and glial cells). Therefore, MEK1/
2 inhibition is an exciting novel treatment strategy for delayed
neurological complications after transient GCI. Currently, we
have extensive knowledge of the effect of MEK1/2 inhibition
on extra-parenchymal vascular changes, but the effect of
MEK1/2 inhibition on microvascular changes after GCI is
largely unknown. In this study, we investigated the GCI-
induced changes of the cerebral intraparenchymal microvascu-
lature and the effect of treatment with aMEK1/2 inhibitor post-
GCI on these microvascular changes 72 h after GCI induction
in a proteome study, since we have previously shown that at
72 h post-GCI, maximal contractile receptor contractility of the
extra-parenchymal vasculature is occurring and neuronal cell
death is starting to appear (Johansson et al. 2014).
The effects of GCI on the cerebral microvasculature are
largely unknown and may contribute to the development of
delayed neurological damage along with the changes in the
large extra-parenchymal ar ter ies af ter GCI. The
intraparenchymal vasculature is an integrated part of the brain
parenchyma whose local contractile state is primarily regulat-
ed by factors released by local astrocytes and neurons (Attwell
et al. 2010). Another important feature of the cerebral micro-
vasculature is that it constitutes a part of the BBB whose key
role is protecting the vulnerable neurons from toxic com-
pounds in the blood and creating a specialized environment
for energy-efficient coordinated neuronal function and pro-
cessing (Bradbury 1993). Due to these specialized character-
istics of the intraparenchymal vasculature distinguishing it
from the extra-parenchymal vasculature, it is highly relevant
to investigate GCI-induced changes in the cerebral
microvasculature.
Large-scale proteomics using advanced mass spectrometry
allows precise in-depth mapping of relative but quantitative
expressional changes in a given tissue at a given time point
(Steen and Mann 2004). This technique is a valuable tool
when examining the effects of a disease on a specific tissue
or cell type and the effect of new treatments on these tissue-
specific expressional changes. In this study, we performed a
proteomic screen of the isolated cerebral microvasculature that
enabled us to obtain a global map of expressional changes
after GCI compared to sham-operated animals as well as the
effect of treatment with a MEK1/2 inhibitor on these GCI-
induced expressional changes.
Materials and Methods
Experimental Global Cerebral Ischemia in Rats
MaleWistar rats (9–11 weeks, 290–350 g, Taconic, Denmark)
were used for the experiments, and they were provided with
standard rat chow and water and were housed under 12-h
light/dark cycle conditions. All animal experiments were car-
ried out in accordance with EU guidelines (directive 2010/63/
EU on the protection of animals used for scientific purposes)
and the experimental protocol was approved by the Danish
Experimental Animal Inspectorate (licence no. 2012-15-
2934-00726).
Transient GCI was induced in male rats by occluding the
common carotid arteries combined with systemic hypoten-
sion, which disrupts the blood flow to the forebrain
(Johansson et al. 2012; Smith et al. 1984) resulting in fore-
brain ischemia. The rat was anaesthetized with 4% isoflurane
in a mixture of O2 and N2O (30:70), intubated and supplied
with 2% isoflurane during the surgery. The tail artery was
cannulated for measurement of mean arterial blood pressure
(MABP) and a tail vein cannulated for the administration of
the muscle relaxant Norcuron (1.3 mL/h, Nomeco, Denmark).
The MABP was lowered to 35–40 mmHg by withdrawing
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blood from the jugular vein followed by clamping of the com-
mon carotid arteries for 15 min. During the entire procedure,
body and scalp temperature at 37 ± 0.5 °C was ensured by
thermometers in the rectum and subcutaneously above the
scalp. Analgesics (Rimadyl®, Carprofen 5 mg/kg, Nomeco,
Denmark) were supplied during surgery and again daily until
euthanasia. The rats were housed individually 72 h after the
surgery and euthanized by sedation in a mixture of CO2 and
O2 followed by decapitation.
Experimental Groups and Treatment Protocol
A total of 30 rats were included in this study: 18 rats for the
proteomics screen and 12 rats for flow cytometry. The rats for
the proteomic screen were divided into three groups: (1)
sham-operated treated with vehicle (500 μL DMSO, Sigma-
Aldrich, Denmark), (2) GCI treated with vehicle and (3) GCI
treated with the MEK1/2 inhibitor U0126 (30 mg/kg in
500 μL DMSO, LC Laboratories, USA). Treatment was allo-
cated in a randomized fashion before the operations and given
intraperitoneally at 0, 12, 24, 36, 48 and 60 h after sham or
GCI induction. Seventy-two hours after the surgery, the ani-
mals were euthanized and the brains snap-frozen in ice-cold 2-
methylbutane (Sigma-Aldrich) and stored at −80 °C until
microvessel purification for the proteomic screen (Pardridge
et al. 1987). For flow cytometry analysis, single-cell suspen-
sion with intraparenchymal microvasculature was isolated
from the brains immediately after euthanasia 72 h after GCI
(six rats) or sham (six rats) operation. Physiological data from
different groups of animals were tested statistically by one-
way ANOVA with Bonferroni’s post test, and p < 0.05 was
accepted as statistical significant.
Isolation of the Cerebral Microvasculature
for the Proteomic Screen
The microvasculature of the six brains in each of the three
treatment groups (sham with vehicle, GCI with vehicle and
GCI with U0126) were purified separately but on the same
day, respectively. Furthermore, individual brains within a
group remained separate during preparation of the vascular
fraction. The brains were thawed on ice followed by removal
of extra-parenchymal vasculature and striatal brain structures
in ice-cold physiological buffer solution 1 (PBS1) with the
following composition: 138 mM NaCl, 10 mM HEPES,
4 mMKCl and 2.2 mMCaCl2. The isolated cortical structures
were gently homogenized in ice-cold PBS1, and the homog-
enate was centrifuged at 800×g for 5 min at 4 °C. The super-
natant was discarded, and the pellet was resuspended in 10mL
of PBS1 with 15% dextran (MW range 64,000 to 74, 000,
Sigma-Aldrich) and centrifuged at 20,000×g for 10 min at
4 °C. This resulted in a separation of the vasculature (pellet)
and the neuronal/glial tissue (cholesterol-rich layer on top of
the dextran solution). The pellet was resuspended in 10 mL of
PBS1 with 15% dextran and subjected to a second round of
centrifugation at 20,000×g. The pellet of enriched microvas-
culature was then resuspended in PBS1, transferred to a
40-μm cell strainer (Falcon, Corning®, VWR, Denmark)
and washed with 10 mL of PBS1. The vascular structures
retained on the filter were transferred to an Eppendorf tube,
and 400 μL of prewarmed enzyme mixture (0.2%
collagenase/dispase (Roche, Switzerland), 0.013% elastase
(Sigma-Aldrich) and 2% BSA (Sigma-Aldrich)) was added
followed by incubation at 37 °C for 15 min with frequent
pipetting. The enzymatic activity was terminated by adding
4 mL of ice-cold Dulbecco’s modified medium (Gibco, Life
Technologies, Denmark) with 20% foetal bovine serum
(Thermo Fischer Scientific, USA) to the samples, and the
vascular structures were washed on a 40-μm cell strainer.
The sample of the microvasculature retained on the cell strain-
er was collected by forceps, snap-frozen in an Eppendorf tube
on dry ice and stored at −80 °C until protein purification. The
samples were blinded prior to protein purification and mass
spectrometry analysis.
Protein Purification, Peptide Preparation
and Fractionation for Mass Spectrometry
The samples of cerebral intraparenchymal vasculature were
dounce-homogenized in 0.1 M Na2CO3 (ice-cold) containing
protease and phosphatase inhibitors (Roche, Meylan, France)
and then sonicated for 2 × 20 s on ice. Homogenates were
ultra-centrifuged at 150,000×g for 1.5 h. Pellets (membrane
fractions) were resuspended in 6 M urea/2 M thiourea, super-
natants (soluble fractions) were precipitated using 20% tri-
chloroacetic acid, and pellets from this precipitation were re-
suspended in 6 M urea/2 M thiourea. All samples were re-
duced in 10 mM dithiothreitol and then alkylated using
20 mM iodoacetamide. Lysyl endopeptidase (Wako, Osaka,
Japan) was added for 3 h followed by sixfold sample dilution
in 50 mM triethylammonium bicarbonate. Trypsin (Promega,
Madison,WI, USA) was added at a ratio of 1:40 (w/w) and left
for 18 h to digest. Digests were acidified with formic acid (2%
final concentration), and the protein content of aliquots was
quantified using amino acid analysis. Maximum equal
amounts of protein from each sample were labelled with
iTRAQ four-plex reagent according to the manufacturer’s in-
structions (AB Sciex, MA, USA), and equal labelling was
confirmed on a Bruker UltraFlex MALDI MS (Bruker, MA,
USA), and the three sample groups (sham with vehicle, GCI
with vehicle and GCI with U0126) were combined to give
equal reporter intensity.
Combined peptide samples were then enriched with titani-
um dioxide for isolation of glycosylated peptides. Briefly, the
samples were incubated with titanium dioxide at a ratio of
0.6 mg Tio2/100 μg peptide, in 80% acetonitrile (ACN), 5%
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trifluroacetic acid (TFA) and 1 M glycolic acid. Flow through
from this incubation became the ‘non-modified’ fraction, one
with membrane peptides and one with cytosolic peptides.
After incubation (10 min), TiO2 beads were washed sequen-
tially with 80% ACN/5% TFA, 80% ACN/0.1% TFA and
20%ACN/0.1% TFA. The peptides were eluted from titanium
using 25% ammonia water (pH 11; Sigma). These became the
titanium dioxide elution fractions. All peptide samples were
cleaned up separately on homemade R3 columns (PerSeptive
Biosystems, Framingham, MA, USA) and then dried down
for hydrophilic interaction chromatography (HILIC). Peptide
samples were resuspended in 90% ACN/0.1% TFA and load-
ed onto a micro-HILIC chromatography system. HILIC resin
was TSK-Gel Amide 80 (Tosoh Bioscience, Japan). The sam-
ples were separated over a gradient of 90 to 60% organic
solvent over 30 min and then 60–0% over 15 min. Fractions
were collected every minute at absorbances over 500 mAU
and every 5 min otherwise. All fractions were lyophilized
prior to LC-MS analysis.
Mass Spectrometry
Dry peptide fractions were resuspended in 0.1% formic acid
and loaded onto a Thermo EasyLC. SeparateMS/MS analyses
were performed for the membrane, cytosolic and glycosylated
peptides. The peptides were eluted using a 0–34% organic
gradient over 70 min and then 34–100% over 20 min. All
LC-MS runs were performed on 75-μm-inner-diameter col-
umns, packed with C18 material (Dr. Maisch, Ammerbuch-
Entringen, Germany). Mass spectrometry was performed
using higher-energy collisional dissociation (HCD) fragmen-
tation on a Thermo LTQ Velos (Thermo Fisher Scientific,
Bremen, Germany). Quantification was performed on reporter
tags at m/z 114, 115 and 116. MS settings: a full MS scan in
the mass area of 400–1800 Da was performed in the Orbitrap
with a resolution of 30,000 FWHM and a target value of
1 × 106 ions. For each full scan, the seven most intense ions
(>+1 charge state) were selected for HCD and detected at a
resolution of 7500 FWHM. HCD settings: threshold for ion
selection was 20,000, the target value of ions used for HCD
was 1 × 105, activation time was 1 ms, isolation window was
2.5 Da, and normalized collision energy was 48.0.
All data were searched using Thermo Proteome Discoverer
(version 1.3.0.339) and Mascot (v2.2, Matrix Science Ltd.,
London, UK) allowing for variable methionine oxidation
and protein N-terminal acetylation. iTRAQ labelling was set
as a fixed modification, along with cysteine carbamidometh-
ylation. Enzyme specificity was set for trypsin, with two
missed cleavages allowed. Precursor mass tolerance was
10 ppm, and fragment mass tolerance was set to 0.05 Da.
Data were searched against a Swiss-Prot rat database
(UniProtKB/Swiss-Prot 2012_10). Data were filtered to 1%
peptide FDR with a decoy approach using the percolator
function in Proteome Discoverer, filtered to remove Mascot
scores less than 18 and limited to the best matching peptide for
each scan, as described previously (Engholm-Keller et al.
2012). Data were exported from Proteome Discoverer and
manually normalized to protein median values across an entire
labelling experiment to correct for protein abundance varia-
tion. Protein and peptide regulation was defined based on the
iTRAQ ratio exceeding two standard deviations from the me-
dian ratio for a given tag.
Flow Cytometry
We used flow cytometry for blinded expressional determina-
tion of lamininβ2, clathrin heavy chain (HC) and nidogen2 in
the VSMCs of the cerebral intraparenchymal vasculature of
the forebrain from sham and GCI rats. The hind part of the
brain (cerebrum behind MCA and cerebellum) was discarded
and the remaining extra-parenchymal vasculature removed
from the forebrain structures. The isolation of a single-cell
population of the forebrain structures including the
intraparenchymal vasculature was performed by a novel tech-
nique based on previous protocols, advanced in the our labo-
ratory and described in detail in the following (Navone et al.
2013; van Beijnum et al. 2008). The tissue was disrupted
mechanically with a surgical scalpel followed by enzymatic
digestion with Liberase TM Research Grade (Roche,
Switzerland) for 1.5 h at 37 °C. Red blood cells, granulocytes,
non-vital cells and cell debris were removed from the cell
suspension by centrifugation on a Ficoll-Paque PLUS (GE
Healthcare, Denmark) gradient for 30 min, 400×g at room
temperature (RT). The interphase of the Ficoll gradient was
isolated, leaving us with viable neurons, astrocytes and vas-
cular cells and this cell suspension was fixated in 4% parafor-
maldehyde for 30 min, then washed with PBS and kept herein
until staining and run of experiments.
The single-cell population was permeabilized with 0.25%
Triton X-100 PBS (PBS-T, Chemicon, Sweden) for 30 min at
RT and incubated in blocking buffer (5% normal donkey se-
rum in PBS) for 2 h at RT. The cell suspensions were stained
overnight at 4 °C with primary goat anti-smooth muscle actin
22 (anti-SM22) (1:100, ab10135, Abcam, Cambridge, UK),
primary rabbit anti-myosin HC (1:100, myosin HC, ab82541,
Abcam), goat isotope control IgG (5 μg/mL, ab37373,
Abcam) or rabbit isotype control IgG (5 μg/mL, ab37416,
Abcam) in blocking buffer. Subsequently, the cell suspensions
were incubated with Alexa Fluor 488-conjugated donkey anti-
goat IgG (1:100, 505-545-147, Jackson ImmunoResearch,
PA, USA) or allophycocyanin (APC)-conjugated donkey
an t i - r abb i t IgG (1 :100 , 711 -136 -152 , J ackson
ImmunoResearch) for 2 h in the dark at RT.
Next, the cell suspensions were incubated with one of the
following primary antibodies: mouse anti-lamininβ2 (1:10,
MAB2066, R&D systems, MN, USA), rabbit anti-clathrin
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HC (1:100, ab21679, Abcam), goat anti-nidogen2 (1:20, sc-
26133, Santa Cruz, USA), mouse isotope control IgG (10 μg/
mL, ab18443, Abcam), rabbit isotype control IgG (10 μg/mL,
ab37416, Abcam) or goat isotype control IgG (10 μg/mL,
ab37373, Abcam) in blocking buffer overnight at 4 °C.
Excess primary antibody was removed followed by incuba-
tion with DyLight 405-conjugated donkey anti-mouse IgG
(1:100, 715-475-150, Jackson ImmunoResearch), APC-
conjugated donkey anti-rabbit IgG (1:100, 705-545-147,
Jackson ImmunoResearch) or Alexa Fluor 488-conjugated
donkey anti-goat IgG (1:100, 705-545-147, Jackson
ImmunoResearch) for 2 h in the dark at RT. Finally, excess
secondary antibody was removed and the cell suspensions
were diluted to a final volume of 0.5 mL with PBS.
The double-stained cell suspensions were analysed by
fluorescent-activated cell sorting (FACS) on the BD
FACSVerse machine (BD Biosciences, NJ, USA).
Fluorescence was induced with a 405-nm violet laser, a 488-
nm blue laser and a 640-nm red laser. The single-cell popula-
tion was defined from the forward scatter versus side scatter
plot of all events (supplementary figure; S1 Fig. A and B), and
in each experiment for each antibody used, we defined the
antibody-specific signal according to the IgG control (supple-
mentary figure; S1 Fig. C–H). Data were analysed by the BD
FACSuite Software. The sham and GCI operations, tissue iso-
lation and FACS analyses were performed in pairs, and there-
fore, results were analysed with Student’s two-tailed paired t
test and p < 0.05 was accepted as statistical significant.
Results
Physiological Parameters
For the proteomic screen, we had microvasculature from three
groups of rats: GCI + U0126 treatment, GCI + vehicle
(DMSO) and sham + vehicle (DMSO). All physiological pa-
rameters from the surgeries are presented in Table 1 and were
within acceptable physiological limits. Furthermore, there
were no significant differences in the physiological parame-
ters when comparing these three groups or with animals op-
erated for validation with flow cytometry (Table 1).
Overview of Experimental Setup and Groups Analysed
in the Proteome
The proteomic screen was a tandem mass spectrometry anal-
ysis where relative expressional changes were calculated on
the basis of iTRAQ labelling. Prior to mass spectrometry, the
protein mixture from three to six animals was divided into
three fractions analysed separately by mass spectrometry: gly-
cosylated, membrane and cytosolic proteins. A total of 336
glycosylated proteins, 1214 membrane proteins and 405
cytosolic proteins were identified. Upregulated proteins iden-
tified in the glycosylated, membrane and cytosolic fractions
were pooled into one list, and likewise, downregulated pro-
teins identified in the glycosylated, membrane and cytosolic
fractions were pooled into one list for analysis and biological
interpretation. We compared the list of proteins upregulated
after GCI (vehicle) relative to sham with the list of proteins
upregulated after GCI treated with the MEK1/2 inhibitor
U0126 relative to sham. We identified 50 proteins for whom
the increased expression was found to persist independent of
treatment with U0126 (S1 Table) and 82 and 105 proteins that
were uniquely upregulated either after vehicle (S3 Table) or
U0126 treatment (S5 Table), respectively. Likewise, we com-
pared the list of proteins downregulated after GCI (vehicle)
relative to sham with the list of proteins downregulated after
GCI treated with U0126 relative to sham. We identified 30
proteins for whom the decreased expression persisted inde-
pendently of treatment with U0126 (S2 Table) and 42 and
56 proteins that were uniquely downregulated either after ve-
hicle (S4 Table) or U0126 treatment (S6 Table), respectively.
Proteomic Changes in the Cerebral Microvasculature
After GCI
A total of 132 proteins were upregulated (Table 2), and 72
proteins were downregulated (Table 3) 72 h after GCI
(vehicle) compared to sham. We visualized the proteins that
were upregulated and downregulated after GCI separately
with STRING (string-db.org, version 10), an online database
of known and predicted protein-protein interactions
(Szklarczyk et al. 2015).
Proteins Upregulated
STRING revealed a detailed map of known and predicted
protein-protein interactions of the proteins found to be upreg-
ulated after GCI compared to sham (Fig. 1). Within this map,
we identified eight subnetworks (numbered 1–8, Fig. 1)
named according to the biological function of the proteins:
(1) cellular respiration, (2) structural/cytoskeletal proteins,
(3) extracellular matrix (ECM) proteins and fibrinogen, (4)
clathrin-mediated endocytosis, (5) ribosomal proteins, (6)
chromatin structure-related proteins, (7) myelin-associated
proteins and (8) synaptic proteins. Collectively, the network
analysis in Fig. 1 illustrated upregulation of proteins involved
in the mitochondrial part of cellular respiration (tricarboxylic
acid cycle and electron transport chain), clathrin-mediated en-
docytosis, chromatin structure, ribosomal activity, synaptic
activity and myelin composition. Moreover, we found that
different structural/cytoskeletal and ECM proteins were up-
regulated after GCI compared to sham, indicating that a re-
modelling of the cerebral microvasculature might be taking
place.
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Proteins Downregulated
The proteins downregulated 72 h after GCI compared to sham
were also analysed by STRING, creating a map of protein-
protein interactions wherein we identified five subnetworks
(numbered 1–5, Fig. 2) named according to the biological
function of the proteins: (1) cellular respiration, (2) integrin–
collagen interactions, (3) contractile phenotype, (4) G-protein
subunits and (5) sodium-potassium pump. Collectively, this
network analysis illustrates a downregulation of proteins in-
volved in G-protein-coupled receptor (GPCR) signalling, the
contractile phenotype of VSMCs, glycolysis and membrane
potential stability.
Proteomic Changes Normalized by Treatment
with the MEK1/2 Inhibitor U0126
Next, we identified the microvascular proteins that were reg-
ulated after GCI and normalized by treatment with the specific
MEK1/2 inhibitor U0126 (Tables 2 and 3). In Table 2, the list
of proteins upregulated after GCI is divided into groups
representing the subnetworks given in Fig. 1, and within
Table 2, it is stated which of the GCI-induced expressional
changes that were normalized by the U0126 treatment. We
found that at least one of the proteins from each of the eight
groups upregulated (Fig. 1) after GCI was normalized in the
cerebral microvasculature from GCI rats treated with U0126;
however, the U0126 treatment did not normalize the protein
expression of all proteins within any of the eight groups up-
regulated after GCI (Table 2). It is worth highlighting the high
levels of normalization which occurs to the structural proteins
(5 out of 6 proteins, group 2, Table 2) and proteins involved in
clathrin-mediated endocytosis (6 out of 8 proteins, group 4,
Table 2); however, the U0126 treatment was found to have
little effect on the expressional increase of chromatin-structure
related proteins (1 out of 8 proteins normalized, group 6,
Table 2). Additionally, the U0126 treatment normalized the
upregulation of many non-categorized proteins (Table 2).
In Table 3, the list of proteins downregulated after GCI is
divided into groups representing the subnetworks given in
Fig. 2, and within Table 3, it is stated which of the GCI-
induced expressional changes that were normalized by the
U0126 treatment. We found that at least one of the proteins
from each of the five groups downregulated after GCI (Fig. 2)
was normalized in the cerebral microvasculature from GCI
rats treated with U0126 (Table 3). However, post-GCI
U0126 treatment had little effect on the expressional decrease
of contractile proteins (5 out of 14 normalized, group 3,
Table 3) and the protein subunits of the sodium-potassium
ATPase (1 out of 3 normalized, group 5, Table 3).
Additionally, the U0126 treatment normalized the downregu-
lation of many non-categorized proteins (Table 3).
Verification of Selected Proteins
The increased expression of ECM proteins and proteins in-
volved in clathrin-mediated endocytosis identified in the pro-
teomic screen of the cerebral microvasculature after GCI
caught our interest, and we chose to validate the VSMC-
specific expression of clathrin HC, lamininβ2 and nidogen2
after GCI and sham operation by flow cytometry.
Flow cytometry analysis revealed that one distinct popula-
tion of SM22-positive cells (VSMCs) expressed lamininβ2
(upper right quadrant in Fig. 3a, b), and the summary data
showed that a significantly increased percentage of VSMCs
expressed lamininβ2 after GCI compared to sham (p = 0.014,
n = 4, Fig. 3g). We identified two subpopulations of SM22-
positive cells (VSMCs) expressing clathrin HC (upper right
quadrant in Fig. 3b), which were both included in the expres-
sional analysis (Fig. 3e). The percentage of SM22-positive
cells (VSMCs) expressing clathrin HC tended to increase after
GCI compared to sham, although this was not statistically
significant (p = 0.082, n = 5, Fig. 3h). We identified two
Table 1 Physiological data from in vivo experiments
MABP (mmHg)
(preischemia)
MABP
(mmHg)
(during)
MABP (mmHg)
(post-ischemia)
pH
(preischemia)
pH (post-
ischemia)
pCO2
(kPa)
pO2 (kPa) Body
temp. (°C)
Cranial
temp.(°C)
Sham, n = 6
(DMSO)
110.1 ± 12.1 – – 7.45 ± 0.1 – 3.4 ± 0.3 16.5 ± 0.5 36.9 ± 0.5 37.0 ± 0.5
GCI, n = 6
(DMSO)
98.4 ± 10.1 39.3 ± 1.6 116.0 ± 11.0 7.42 ± 0.03 7.35 ± 0.06 4.7 ± 0.6 14.4 ± 1.1 36.8 ± 0.4 37.3 ± 0.4
GCI, n = 6
(U0126)
104.3 ± 8.4 41.0 ± 1.6 106.5 ± 20.6 7.45 ± 0.10 7.41 ± 0.11 3.5 ± 1.5 15.3 ± 1.1 36.9 ± 0.3 36.7 ± 0.3
Sham,
n = 672 h
99.8 ± 13.2 – – 7.37 ± 0.03 – 4.2 ± 0.6 14.9 ± 2.9 36.9 ± 0.2 37.0 ± 0.2
GCI,
n = 672 h
92.2 ± 16.3 35.1 ± 1.7 110.5 ± 8.2 7.38 ± 0.04 7.35 ± 0.03 4.4 ± 0.4 15.7 ± 2.4 37.1 ± 0.1 36.9 ± 0.3
Data given as mean ± standard deviation
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Table 2 Proteins upregulated in the cerebral microvasculature 72 h after GCI (vehicle) compared to sham
Accession
number
Protein name Name in STRING Peptides Normalized
by U0126
Group 1 P08461 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate
dehydrogenase complex, mitochondrial
Dlat 2 Yes
P42123 L-Lactate dehydrogenase B chain Ldhb 1 Yes
Q63362 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 Ndufa5 1 Yes
O35077 Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic Gpd1 1 Yes
P20070 NADH–cytochrome b5 reductase 3 Cyb5r3 1 Yes
P97700 Mitochondrial 2-oxoglutarate/malate carrier protein Slc25a11 1 Yes
Q6AXV4 Sorting and assembly machinery component 50 homolog Samm50 4 Yes
Q4QQV3 Protein FAM162A Fam162a 1 Yes
B0K020 CDGSH iron–sulphur domain-containing protein 1 Cisd1 6 Yes
Q5XIN6 LETM1 and EF-hand domain-containing protein 1, mitochondrial Letm1 2 Yes
P04166 Cytochrome b5 type B Cyb5b 5 –
P05708 Hexokinase-1 Hk1 1 –
P15999 ATP synthase subunit alpha, mitochondrial Atp5a1 2 –
O54715 V-type proton ATPase subunit S1 Atp6ap1 1 –
P10719 ATP synthase subunit beta, mitochondrial Atp5b 1 –
Q99NA5 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial Idh3a 1 –
Q05962 ADP/ATP translocase 1 Slc25a4 7 –
Q3KR86 Mitochondrial inner membrane protein (fragment) Immt 1 –
Q9Z2L0 Voltage-dependent anion-selective channel protein 1 Vdac1 1 –
P81155 Voltage-dependent anion-selective channel protein 2 Vdac2 3 –
P62815 V-type proton ATPase subunit B, brain isoform Atp6v1b2 1 –
Group 2 P31000 Vimentin Vim 1 Yes
Q63862 Myosin-11 (fragments) Myh11 3 Yes
Q63355 Unconventional myosin-Ic Myo1c 1 Yes
P28023 Dynactin subunit 1 Dctn1 1 Yes
P62738 Actin, aortic smooth muscle Acta2 2 Yes
Q5XIF6 Tubulin alpha-4A chain Tuba4a 1 –
Group 3 B5DFC9 Nidogen2 Nid2 1 Yes
P15800 Laminin subunit beta Lamb2 2 Yes
Q9EQP5 Prolargin Prelp 2 Yes
P47853 Biglycan Bgn 1 Yes
P06399 Fibrinogen alpha chain Fga 6 Yes
P02680 Fibrinogen gamma chain Fgg 16 Yes
Q68VK5 Tetraspanin-5 Tspan5 1 Yes
P16086 Spectrin alpha chain, non-erythrocytic 1 Sptan1 1 Yes
Q9EPF2 Cell surface glycoprotein MUC18 Mcam 1 Yes
P32736 Opioid-binding protein/cell adhesion molecule Opcml 2 Yes
Q1WIM3 Cell adhesion molecule 3 Cadm3 2 Yes
P14480 Fibrinogen beta chain Fgb 1 –
O35112 CD166 antigen Alcam 7 –
O88775 Embigin Emb 6 –
Q99P82 Claudin-11 Cldn11 2 –
P13852 Major prion protein Prnp 1 –
P01830 Thy-1 membrane glycoprotein Thy1 3 –
P49134 Integrin beta-1 Itgb1 1 –
Group 4 P84092 AP-2 complex subunit mu Ap2m1 1 Yes
P62744 AP-2 complex subunit sigma Ap2s1 2 Yes
P62944 AP-2 complex subunit beta Ap2b1 1 Yes
O55012 Phosphatidylinositol-binding clathrin assembly protein Picalm 1 Yes
Q07647 Solute carrier family 2, facilitated glucose transporter member 3 Slc2a3 2 Yes
Q4V8H8 EH domain-containing protein 2 Ehd2 1 Yes
P11442 Clathrin heavy chain 1 Cltc 1 –
P61206 ADP-ribosylation factor 3 Arf3 1 –
Group 5 P19804 Nucleoside diphosphate kinase B Nme2 1 Yes
P41123 60S ribosomal protein L13 Rpl13 1 Yes
P62909 40S ribosomal protein S3 Rps3 1 Yes
P62271 40S ribosomal protein S18 Rps18 1 Yes
P62912 60S ribosomal protein L32 ENSRNOG00000032605 1 Yes
P49242 40S ribosomal protein S3a Rps3a 6 –
P27952 40S ribosomal protein S2 Rps2 1 –
P21533 60S ribosomal protein L6 Rpl6 1 –
Group 6 Q00715 Histone H2B type 1 H2b 9 Yes
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Table 2 (continued)
Accession
number
Protein name Name in STRING Peptides Normalized
by U0126
P84245 Histone H3.3 H3f3b 2 –
A9UMV8 Histone H2A.J ENSRNOG00000033045 6 –
P15865 Histone H1.4 Hist1h1d 2 –
P0C0S7 Histone H2A.Z H2afz 2 –
Q6P747 Heterochromatin protein 1-binding protein 3 Hp1bp3 3 –
Q02874 Core histone macro-H2A.1 H2afy 1 –
P62804 Histone H4 Hist2h4 6 –
Group 7 P07722 Myelin-associated glycoprotein Mag 3 Yes
P02688 Myelin basic protein Mbp 1 Yes
Q812E9 Neuronal membrane glycoprotein M6-a Gpm6a 1 Yes
Q0ZHH6 Atlastin-3 Atl3 1 Yes
Q64548 Reticulon-1 Rtn1 1 Yes
P60203 Myelin proteolipid protein Plp1 22 –
Q63345 Myelin-oligodendrocyte glycoprotein Mog 2 –
Group 8 Q02563 Synaptic vesicle glycoprotein 2A Sv2a 8 Yes
P60905 DnaJ homolog subfamily C member 5 Dnajc5 6 Yes
P61265 Syntaxin-1B Stx1b 1 Yes
P21707 Synaptotagmin-1 Syt1 2 Yes
P61765 Syntaxin-binding protein 1 Stxbp1 1 –
P07825 Synaptophysin Syp 1 –
P19491 Glutamate receptor 2 Gria2 1 –
Q9JI12 Vesicular glutamate transporter 2 Slc17a6 1 –
Non-categorized P07340 Sodium/potassium-transporting ATPase subunit beta-1 Atp1b1 1 Yes
P11506 Plasma membrane calcium-transporting ATPase 2 Atp2b2 1 Yes
P48037 Annexin A6 Anxa6 2 Yes
P25122 Potassium voltage-gated channel subfamily C member 1 Kcnc1 1 Yes
P46101 Dipeptidyl aminopeptidase-like protein 6 Dpp6 2 Yes
P25099 Adenosine receptor A1 Adora1 1 Yes
O09175 Aminopeptidase B Rnpep 1 Yes
P47752 Sphingosine 1-phosphate receptor 2 S1pr2 1 Yes
Q80ZA5 Sodium-driven chloride bicarbonate exchanger Slc4a10 2 Yes
Q9WVR6 Large neutral amino acids transporter small subunit 2 Slc7a8 1 Yes
Q9Z1E1 Flotillin-1 Flot1 2 Yes
P31662 Sodium-dependent neutral amino acid transporter SLC6A17 Slc6a17 4 Yes
P33124 Long-chain-fatty-acid–CoA ligase 6 Acsl6 1 Yes
P70580 Membrane-associated progesterone receptor component 1 Pgrmc1 2 Yes
P07687 Epoxide hydrolase 1 Ephx1 1 Yes
Q6AXM8 Serum paraoxonase/arylesterase 2 Pon2 1 Yes
P36365 Dimethylaniline monooxygenase [N-oxide-forming] 1 Fmo1 2 Yes
P47819 Glial fibrillary acidic protein Gfap 3 Yes
Q9JJW1 Tetraspanin-2 Tspan2 1 Yes
Q07936 Annexin A2 Anxa2 2 Yes
Q5FVI4 Cell cycle exit and neuronal differentiation protein 1 Cend1 1 Yes
P97546 Neuroplastin Nptn 2 Yes
P14668 Annexin A5 Anxa5 4 Yes
P07936 Neuromodulin Gap43 1 Yes
Q80U96 Exportin-1 Xpo1 1 Yes
Q9WVC0 Septin-7 sep–07 1 Yes
P97536 Cullin-associated NEDD8-dissociated protein 1 Cand1 2 Yes
P97710 Tyrosine-protein phosphatase non-receptor type substrate 1 Sirpa 1 Yes
P12346 Serotransferrin Tf 1 Yes
O08590 Membrane primary amine oxidase Aoc3 7 Yes
P46462 Transitional endoplasmic reticulum ATPase Vcp 1 Yes
Q6AXX6 Redox-regulatory protein FAM213A RGD1309676 2 Yes
Q9EQT5 Tubulointerstitial nephritis antigen-like Tinagl1 1 Yes
P00762 Anionic trypsin-1 Prss1 6 –
P05371 Clusterin Clu 1 –
P10252 CD48 antigen Cd48 1 –
P11654 Nuclear pore membrane glycoprotein 210 Nup210 1 –
P13596 Neural cell adhesion molecule 1 Ncam1 5 –
P14740 Dipeptidyl peptidase 4 Dpp4 2 –
P18418 Calreticulin Calr 1 –
P19643 Amine oxidase Maob 2 –
J Mol Neurosci (2017) 61:396–411 403
subpopulations of myosin HC-positive cells (VSMCs) ex-
pressing nidogen2 (upper right quadrant in Fig. 3c), which
were both included in the expressional analysis (Fig. 3f).
The percentage of VSMCs expressing nidogen2 was signifi-
cantly increased after GCI compared to sham (p = 0.026,
n = 5, Fig. 3i).
Discussion
This is the first study to generate a proteomic in-depth char-
acterization of the cerebral microvascular proteins regulated
after GCI and how treatment with the MEK1/2 inhibitor
U0126 normalized several of these expressional changes.
The possible functional consequences of the upregulated and
downregulated subnetworks of expressional changes identi-
fied in Figs. 1 and 2 are discussed by dividing the important
GCI-induced cerebral microvascular changes into nine main
categories. Within each of the nine categories, the effect of the
U0126 treatment on the GCI-induced expressional changes is
discussed (Tables 2 and 3). The nine categories of GCI-
induced expressional changes are: 1. Altered cellular respira-
tion, 2. Remodelling of the ECM, 3. Decreased contractile
phenotype, 4. Increased clathrin-mediated endocytosis, 5.
Increased expression of chromatin structure-related protein,
6. Increased ribosomal protein expression, 7. Increased syn-
aptic activity, 8. Altered G-protein signalling and 9. Instability
of the membrane potential.
1. Altered cellular respiration: we found a decreased expres-
sion of glycolytic enzymes and an increased expression of
citric acid cycle enzymes and mitochondrial proteins in-
volved in adenosine triphosphate (ATP) production and L-
lactate dehydrogenase. This indicates decreased glycoly-
sis activity and increased lactate metabolism and mito-
chondrial production of ATP in the cerebral microvascu-
lature after GCI. However, we also found a decreased
expression of a few mitochondrial proteins involved in
ATP production. Treatment with U0126 normalized the
GCI-induced decrease in glycolytic enzymes and mito-
chondrial proteins and the GCI-induced increase of L-lac-
tate dehydrogenase, whereas the U0126 treatment only
partly normalized the expressional increase of citric acid
cycle enzymes and proteins involved in mitochondrial
ATP production. Collectively, this indicates that the
U0126 treatment partly normalizes the GCI-induced al-
tered cellular respiration of the cerebral microvascular
cells. The effect of the U0126 treatment on lactate metab-
olism might also be a secondary effect as increased lactate
metabolism has been shown to correlate with cerebral
ischemic damage (Dienel 2014).
2. Remodelling of the ECM: we found increased expression
of the extracellular proteins nidogen2, prolargin,
lamininβ2 and biglycan and a decreased expression of
collagen type I (α1 and α2 chain) and integrins α7, β1
and β4. The expressions of integrin and ECM proteins
were normalized by the U0126 treatment, whereas the
expression of collagen type I was downregulated both in
vehicle- and in U0126-treated animals. We also found
increased expression of fibrinogen after GCI, which was
partly normalized by the U0126 treatment (2 out of 3
proteins normalized). Interestingly, fibrinogen has previ-
ously been shown to deposit in the microvascular wall
after cerebral ischemia (Baeten and Akassoglou 2011).
Remodelling of the ECMmay decrease the elasticity of the
cerebral intraparenchymal arterioles, and such pathological
arterial stiffness is thought to be involved in various cerebro-
vascular disorders (Martinez-Lemus et al. 2009a), and there-
fore, these expressional changes caught our interest.
Extracellular proteins are produced and secreted from
VSMCs, endothelial cells and perivascular astrocytes, and
we find that the percentage of VSMCs expressing lamininβ2
and nidogen2 increased 72 h after GCI (Fig. 3). Nidogen2 is
an ECM protein primarily found in the basement membrane
between the endothelial cells and VSMCs (Ho et al. 2008),
Table 2 (continued)
Accession
number
Protein name Name in STRING Peptides Normalized
by U0126
P23785 Granulins Grn 1 –
P25235 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase
subunit 2
Rpn2 1 –
Q5I0E7 Transmembrane emp24 domain-containing protein 9 Tmed9 2 –
Q63081 Protein disulphide-isomerase A6 Pdia6 1 –
Q64428 Trifunctional enzyme subunit alpha, mitochondrial Hadha 1 –
Q80Z70 Protein sel-1 homolog 1 Sel1l 1 –
Q9WVK7 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Hadh 1 –
Proteins are divided into groups according to the subnetworks identified in Fig. 1. Accession number, protein name and name in STRING are given,
along with the number of upregulated peptides; each protein identification was based upon and whether post-GCI treatment with the MEK1/2 inhibitor
U0126 normalized the expression of a given protein
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Table 3 Proteins downregulated in the cerebral microvasculature 72 h after GCI compared to sham
Accession
number
Protein name Name in STRING Peptides Normalized by
U0126
Group 1 P04797 Glyceraldehyde-3-phosphate dehydrogenase Gapdh 1 Yes
P19511 ATP synthase F(0) complex subunit B1, mitochondrial Atp5f1 1 Yes
P05065 Fructose-bisphosphate aldolase A Aldoa 3 Yes
P05708 Hexokinase-1 Hk1 2 Yes
Q641Y2 NADH dehydrogenase [ubiquinone] iron–sulphur protein
2, mitochondrial
Ndufs2 1 Yes
P48500 Triosephosphate isomerase ENSRNOG00000015290 1 Yes
Q5RJQ4 NAD-dependent protein deacetylase sirtuin-2 Sirt2 1 Yes
P16036 Phosphate carrier protein, mitochondrial Slc25a3 1 Yes
P01946 Haemoglobin subunit alpha-1/2 Hba2 2 Yes
Q66HD0 Endoplasmin Hsp90b1 2 Yes
P15429 Beta-enolase Eno3 1 Yes
P11240 Cytochrome c oxidase subunit 5A, mitochondrial Cox5a 2 Yes
P13635 Ceruloplasmin Cp 1 Yes
Q794F9 4F2 cell surface antigen heavy chain Slc3a2 3 –
Group 2 Q63258 Integrin alpha-7 Itga7 1 Yes
P49134 Integrin beta-1 Itgb1 5 Yes
Q64632 Integrin beta-4 Itgb4 1 Yes
P02454 Collagen alpha-1(I) chain Col1a1 39 –
P02466 Collagen alpha-2(I) chain Col1a2 3 –
Q9Z1P2 Alpha-actinin-1 Actn1 1 –
Group 3 P02564 Myosin-7 Myh7 12 Yes
Q29RW1 Myosin-4 Myh4 3 Yes
P12847 Myosin-3 Myh3 1 Yes
Q63610 Tropomyosin alpha-3 chain Tpm3 2 Yes
P58775 Tropomyosin beta chain Tpm2 5 Yes
P02563 Myosin-6 Myh6 2 –
P02600 Myosin light chain 1/3, skeletal muscle isoform Myl1 1 –
P04462 Myosin-8 (fragment) Myh1 1 –
P08733 Myosin regulatory light chain 2, ventricular/cardiacmuscle
isoform
Myl2 2 –
P13413 Troponin I, slow skeletal muscle Tnni1 2 –
P16409 Myosin light chain 3 Myl3 2 –
P68136 Actin, alpha skeletal muscle Acta1 8 –
P00564 Creatine kinase M-type Ckm 7 –
P11507 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Atp2a2 3 –
Group 4 P54311 Guanine nucleotide-binding protein G(I)/G(S)/G(T) sub-
unit beta-1
Gnb1 2 Yes
P04897 Guanine nucleotide-binding protein G(i) subunit alpha-2 Gnai2 1 Yes
P10824 Guanine nucleotide-binding protein G(i) subunit alpha-1 Gnai3 2 –
Group 5 P06686 Sodium/potassium-transporting ATPase subunit alpha-2 Atp1a2 10 Yes
P06685 Sodium/potassium-transporting ATPase subunit alpha-1 Atp1a1 1 –
P07340 Sodium/potassium-transporting ATPase subunit beta-1 Atp1b1 11 –
Non-categorized P97710 Tyrosine-protein phosphatase non-receptor type substrate 1 Sirpa 1 Yes
P70627 Glutamate carboxypeptidase 2 Folh1 1 Yes
Q63633 Solute carrier family 12 member 5 Slc12a5 1 Yes
P31596 Excitatory amino acid transporter 2 Slc1a2 3 Yes
P47942 Dihydropyrimidinase-related protein 2 Dpysl2 1 Yes
Q9JI66 Electrogenic sodium bicarbonate cotransporter 1 Slc4a4 1 Yes
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and genetic ablation of nidogen2 in mice has been shown to
increase vessel wall permeability in the lung (Mokkapati et al.
2012). The increased expression of ECM proteins and de-
creased expression of integrins indicate thickening of the ex-
tracellular basement membrane and its detachment from the
surrounding cel ls , which might compromise the
intraparenchymal vascular function since the proximity of as-
trocytes and vascular cells is important for normal vascular
function (del Zoppo 2009). In support, a previous study
showed thickening of the vascular basement membrane 24 h
after GCI (Wisniewski et al. 1995). Furthermore, the expres-
sion of extracellular proteins was previously shown to in-
crease in the cerebral microvasculature 24 h after GCI in rat
(Haqqani et al. 2005).
Collectively, the results of the proteomic screen and verifi-
cation of a GCI-induced increased percentage of VSMCs ex-
pressing the ECM proteins lamininβ2 and nidogen2 support
the hypothesis of ECM remodelling in the cerebral microvas-
culature after GCI. We speculate that ECM remodelling re-
sults in altered microvascular function contributing to delayed
neuronal damage after GCI.
3. Decreased contractile phenotype: we found a decreased
expression of different isoforms of tropomyosin, myosin
and muscle-specific actin. Additionally, we found an in-
creased expression of cytoskeletal proteins like actin,
vimentin and myosin isoforms involved in intracellular
movement. The U0126 treatment had minor effects on
Table 3 (continued)
Accession
number
Protein name Name in STRING Peptides Normalized by
U0126
P48284 Carbonic anhydrase 4 Car4 1 Yes
P25286 V-type proton ATPase 116 kDa subunit a isoform 1 Atp6v0a1 1 Yes
P54290 Voltage-dependent calcium channel subunit
alpha-2/delta-1
Cacna2d1 2 Yes
P67779 Prohibitin Phb 1 Yes
P02688 Myelin basic protein Mbp 1 Yes
Q3SWT0 Platelet endothelial cell adhesion molecule Pecam1 2 Yes
P58195 Phospholipid scramblase 1 Plscr1 2 Yes
Q920Q0 Paralemmin-1 Palm 4 Yes
P27615 Lysosome membrane protein 2 Scarb2 1 Yes
Q9QWE9 Gamma-glutamyltransferase 5 2 Yes
Q9WTQ2 Podocalyxin Podxl 2 Yes
P0C5X8 Protein tweety homolog 1 Ttyh1 1 Yes
P61265 Syntaxin-1B Stx1b 1 –
P70560 Collagen alpha-1(XII) chain (fragment) 1 –
Q29RW1 Myosin-4 Myh4 2 –
Q62745 CD81 antigen Cd81 2 –
Q63135 Complement component receptor 1-like protein Cr1l 2 –
Q63564 Synaptic vesicle glycoprotein 2B Sv2b 1 –
Q924C3 Ectonucleotide pyrophosphatase/phosphodiesterase family
member 1
Enpp1 2 –
P07153 Dolichyl-diphosphooligosaccharide–protein
glycosyltransferase subunit 1
Rpn1 1 –
D3ZFB6 Proline-rich transmembrane protein 2 Prrt2 1 –
P11167 Solute carrier family 2, facilitated glucose transporter
member 1
Slc2a1 1 –
P14562 Lysosome-associated membrane glycoprotein 1 Lamp1 1 –
P14669 Annexin A3 Anxa3 2 –
P15589 Steryl-sulphatase Sts 1 –
P15684 Aminopeptidase N Anpep 16 –
P21396 Amine oxidase [flavin-containing] A Maoa 1 –
Proteins are divided into groups according to the subnetworks identified in Fig. 2. Accession number, protein name and name in STRING are given,
along with the number of downregulated peptides; each protein identification was based upon and if post-GCI treatment with the MEK1/2 inhibitor
U0126 normalized the expression of the protein
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Fig. 1 Protein interactions of proteins upregulated 72 h after GCI
(vehicle) compared to sham. Protein interactions were analysed by
STRING, and within the overall network, we depicted eight
subnetworks, numbered 1–8 in the figure: (1) cellular respiration, (2)
structural/cytoskeletal proteins, (3) fibrinogen–extracellular matrix
(ECM) interactions, (4) clathrin-mediated endocytosis, (5) ribosomal
proteins, (6) expression of chromatin structure-related proteins, (7)
myelin-associated proteins and (8) synaptic proteins. See Table 2 for a
complete list of the proteins in the network. A known and strong
prediction of a protein-protein interaction is marked by a solid line,
whereas a dashed line indicates a weak protein-protein interaction. The
protein-protein interactions are colour coded based on the nature of the
protein-protein interaction and the colour index given in the figure.
STRING, version 10, string-db.org (Szklarczyk et al. 2015)
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the expressional decrease of contractile protein expression
(5 out of the 14 normalized, Table 3) after GCI.
We hypothesize that the decreased contractile phenotype
identified by expressional changes in the proteome reflected
initial phenotypic switching of VSMCs in the cerebral micro-
vasculature. Phenotypic changes of the VSMCs in different
pathologies like atherosclerosis, hypertension and diabetes are
a widely recognized phenomenon, where the VSMCs trans-
form from a specialized contractile phenotype to a non-
Fig. 2 Protein interactions of proteins downregulated 72 h after GCI
(vehicle) compared to sham. Protein interactions were analysed by
STRING, and within the overall network generated, we depicted five
subnetwork numbered 1–5 in the figure: (1) cellular respiration, (2)
integrin–collagen interactions, (3) contractile phenotype, (4) G-protein
subunits and (5) sodium-potassium pump. See Table 3 for a complete
list of the proteins in the network. A known and strong prediction of a
protein-protein interaction is marked by a solid line, whereas a dashed
line indicates a weak protein-protein interaction. The protein-protein
interactions are colour coded based on the nature of the protein-protein
interaction and the colour index given in the figure. STRING, version 10,
string-db.org (Szklarczyk et al. 2015)
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contractile, proliferative phenotype (Martinez-Lemus et al.
2009b). As found in the proteome, increased expression of
vimentin (cytoskeletal protein) and decreased expression of
collagen type I α1 have been shown to occur in cultured
VSMC stimulated to undergo a phenotypic switch
(Rocchiccioli et al. 2012). Furthermore, biglycan expression
was increased 72 h after GCI, and interestingly, VSMC-
specific overexpression of biglycan in mice was previously
shown to increase vascular hypertrophy and proliferation, in-
dicating that the composition of ECM proteins can contribute
to the induction of a phenotypic switch in VSMCs (Shimizu-
Hirota et al. 2004).
Fig. 3 VSMC-specific expression and verification of expressional
upregulation of lamininβ2, clathrin HC and nidogen2 by flow
cytometry. Single-cell populations were stained with antibodies for the
protein of interest (lamininβ2, clathrin HC and nidogen2) and antibodies
for detection of VSMCs (SM22 or myosin HC). In the single-cell
populations, we detect one population expressing lamininβ2 (a) and
one major and one minor population of cells expressing clathrin HC (b)
and nidogen2 (c). The percentage of VSMCs expressing lamininβ2,
clathrin HC or nidogen2 was determined in the VSMC-specific gate
(SM22 or myosin HC) according to the histograms (d–f). The summary
data showed a significantly increased percentage of VSMCs expressing
lamininβ2 (g, n = 4) and nidogen2 (i, n = 5) after GCI compared to sham.
The percentage of VSMCs expressing clathrin HC tended to increase
after GCI compared to sham but was not significant (h, n = 5). Data
presented as mean ± SEM, and statistical significance was evaluated by
two-tailed, paired Student’s t test, *p < 0.05
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4. Clathrin-mediated endocytosis: the expression of proteins
involved in clathrin-mediated endocytosis increased in the
cerebral microvasculature after GCI (vehicle) compared
to sham and was normalized by treatment with U0126,
except for the expression of clathrin HC. With flow cy-
tometry, we found a tendency towards an increased per-
centage of VSMCs expressing clathrin HC in the cerebral
microvasculature 72 h after GCI (n = 5, p = 0.082).
Increased expression of proteins associated with
clathrin-mediated endocytosis might indicate increased
activity of this mechanism after GCI compared to sham.
Clathrin-mediated endocytosis is primarily involved in
constitutive and stimulated internalization of receptors
(McMahon and Boucrot 2011), and thereby, clathrin-
mediated endocytosis regulates the cellular processes ini-
tiated by these receptors.
5. Increased ribosomal protein expression: we found an in-
creased expression of several ribosomal proteins in the
cerebral microvasculature after GCI (vehicle) compared
to sham, which might indicate increased ribosomal activ-
ity and, thereby, increased translational activity. The GCI-
induced expressional increase in 4 out of 7 ribosomal
proteins was normalized when post-GCI treatment with
the MEK1/2 inhibitor U0126 was applied.
6. Increased expression of chromatin structure-related pro-
teins: the increased expression of several histone isoforms
and other chromatin-related proteins in the cerebral mi-
crovasculature after GCI (vehicle) was not normalized by
treatment with the MEK1/2 inhibitor U0126, expect for
the expression of histone H2B type 1. Histone isoform
composition in the nucleosome and altered expression of
histone isoforms can change epigenetic control of the
DNA and thereby alter gene expression (Findeisen et al.
2013; Zhu et al. 2008), and we hypothesize that the in-
creased expression of several histone isoforms might in-
dicate changes in the epigenetic control and, thereby, the
gene expression of the microvascular cells. Furthermore,
epigenetic mechanisms are known to contribute to the
phenotypic shift of VSMC (Findeisen et al. 2013; Liu
et al. 2015), and we hypothesize that the decreased con-
tractile phenotype of the cerebral microvasculature iden-
tified in the proteomic screen (point 3 above) might be
early indications of a phenotypic switch of the VSMCs.
7. Increased synaptic activity: the expression of several pro-
teins involved in synaptic activity increased after GCI,
which might point to an increased activity of neurons in
close contact with the cerebral microvasculature and
thereby affect the microvascular function in vivo. The
increased expression of proteins involved in synaptic ac-
tivity was partly reversed by the U0126 treatment.
8. Altered G-protein signalling: we found that a decreased
expression of the G-protein subunits β1, α inhibitory 2
(αi2) and α inhibitory 3 (αi3) in the cerebral
microvasculature after GCI compared to sham and
U0126 treatment partly normalized these expressional
changes (2 out of 3 proteins normalized, Table 3).
Changes in G-protein subunit expression might affect
GPCR-mediated signalling coupled to these G-proteins.
Adenylate cyclase is inactivated by αi2 and αi3, and
therefore, adenylate cyclase activity might be increased
due to expressional downregulation of αi2 and αi3. Ion
channels can be activated by the βγ-complex and thereby
alter the membrane potential of the cell and, therefore, the
contractile state of VSMCs; thus, the decreased expres-
sion of β1 might indicate decreased ion channel activity
(Dascal 2001; Edvinsson and Krause 2002).
9. Instability in the membrane potential: we found a de-
creased expression of sodium-potassium ATPase subunits
α1, α2 and β1 after GCI compared to sham which partly
persisted in U0126-treated GCI rats (group 5, Table 3). A
decreased activity of the sodium-potassium ATPase
points to an increased membrane potential and, thereby,
increased cellular vulnerability of the microvascular cells
after GCI. In support, sodium-potassium ATPase activity
was previously shown to be decreased after cerebral is-
chemia (Yang et al. 1992).
Conclusion
In summary, this proteomic screen provides insight into the
expressional changes of the cerebral microvasculature after
GCI compared to sham and which of these expressional
changes that might be normalized when treatment with the
MEK1/2 inhibitor U0126 was applied in GCI rats.
Proteomics is a strong tool to utilize when evaluating the
overall effect of new treatments, especially when testing a
broad kinase inhibitor such as the MEK1/2 inhibitor U0126.
The proteomic data point to many different expressional
changes induced by GCI that can be prevented by early
U0126 treatment; however, it is still unclear which of these
effects are beneficial and which are detrimental. Previous
treatment candidates for delayed cerebral ischemic damage
were primarily neuroprotective and/or focused on individual
downstream targets, whereas our view is that this cannot work
because several different pathological pathways are tran-
scribed and translated after GCI. We have previously shown
that MEK1/2 signalling causes transcription of a large number
of vascular proteins such as contractile receptors, proinflam-
matory molecules and metalloproteinases in the extra-
parenchymal arteries after cerebral ischemia, which we termed
vascular plasticity (Edvinsson and Povlsen 2011). This study
illustrates that GCI induces multiple diverse expressional
changes in the cerebral intraparenchymal vasculature in addi-
tion to the changes of the extra-parenchymal large arteries.
410 J Mol Neurosci (2017) 61:396–411
Moreover, the effect of GCI on the intraparenchymal vascula-
ture is broad and complex and can most likely only be effec-
tively prevented by broad transcriptional inhibition such as
obtained by targeting the MEK1/2 pathway.
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